Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Differences of the new and old Taltz® (ixekizumab) formulation
The new citrate-free formulation is without buffers and contains sucrose as tonicity agent.
Formulation differences
The new citrate-free formulation of ixekizumab
- does not contain any buffer; that is, it is
- citrate free and contains
- sucrose (80 mg/mL) as the tonicity agent.1
The original formulation contains
- sodium citrate dihydrate (5.11 mg/mL) and
- citric acid anhydrous (0.51 mg/mL) as buffers and
- sodium chloride (11.69 mg/mL) as the tonicity agent.1
The ingredients are the same for both the pre-filled pen and syringe.1 Please also see All Taltz ingredients for all ingredients.
This medicinal product contains less than 1 mmol sodium (23 mg) per 80 mg dose, that is to say essentially “sodium-free”.2
Ixekizumab is contraindicated in patients with serious hypersensitivity to the active substance or to any of the excipients.2
Ingredients |
Original Formulation |
New Citrate-free Formulation |
Purpose of Ingredient |
Ixekizumab (active ingredient) |
80 mg |
80 mg |
Active ingredient |
Polysorbate 80 |
0.30 mg |
0.30 mg |
Stabilizer |
Sodium citrate dihydrate |
5.11 mg |
- |
Buffer |
Citric acid anhydrous |
0.51 mg |
- |
Buffer |
Sodium chloride |
11.69 mg |
- |
Tonicity agent |
Sucrose |
- |
80 mg |
Tonicity agent/ stabilizer |
Sodium hydroxide |
- |
q.s. to pH 5.7 |
pH adjustment |
Water for injection |
q.s. to 1.0 mL |
q.s. to 1.0 mL |
Solvent/ vehicle |
Abbreviations: q.s. = quantity sufficient
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Taltz [summary of product characteristics]. Eli Lilly and Company (Ireland) Limited, Ireland
Date of Last Review: 08 December 2021